Oncolytics Biotech Stock (NASDAQ:ONCY)

Ownership Financials Chart Transcripts

Previous Close

$1.15

52W Range

$0.84 - $1.80

50D Avg

$1.06

200D Avg

$1.07

Market Cap

$90.84M

Avg Vol (3M)

$426.51K

Beta

1.35

Div Yield

ONCY Company Profile

Oncolytics Biotech Inc., a development-stage biopharmaceutical company, focuses on the discovery and development of pharmaceutical products for the treatment of cancer. Its lead product is pelareorep, an intravenously delivered immunotherapeutic agent for the treatment of solid tumors and hematological malignancies. Oncolytics Biotech Inc. has a co-development agreement with Merck KGaA and Pfizer Inc. to co-develop pelareorep in combination with paclitaxel and avelumab, a human anti-PD-L1 antibody for the treatment of hormone receptor-positive/human epidermal growth factor 2-negative metastatic breast cancer; and PrECOG LLC. The company was incorporated in 1998 and is headquartered in Calgary, Canada.

Industry

Biotechnology

Sector

Healthcare

Exchange

NASDAQ

ADR

Country

Employees

IPO Date

Oct 05, 2001

Website

ONCY Performance

ONCY Financial Summary

	Dec 23	Dec 22	Dec 21
Revenue	-	-	-
Operating Income	C$-33.79M	C$-28.57M	C$-26.23M
Net Income	C$-27.75M	C$-24.84M	C$-26.30M
EBITDA	C$-33.39M	C$-28.18M	C$-25.66M
Basic EPS	C$-0.41	C$-0.62	C$-0.49
Diluted EPS	C$-0.41	C$-0.62	C$-0.49

Fiscal year ends in Dec 23 | Currency in CAD

Latest Earnings Call Transcripts

Q2 24Aug 01, 24 | 7:55 PM

Q1 24May 09, 24 | 8:48 PM

Q4 23Mar 09, 24 | 1:09 AM

Peer Comparison

Ticker	Company
XFOR	X4 Pharmaceuticals, Inc.
IKT	Inhibikase Therapeutics, Inc.
DAWN	Day One Biopharmaceuticals, Inc.
SCPH	scPharmaceuticals Inc.
CVAC	CureVac N.V.
HOOK	HOOKIPA Pharma Inc.
MCRB	Seres Therapeutics, Inc.
TERN	Terns Pharmaceuticals, Inc.
VIR	Vir Biotechnology, Inc.
KRYS	Krystal Biotech, Inc.
DMAC	DiaMedica Therapeutics Inc.
MIST	Milestone Pharmaceuticals Inc.
LIFE	aTyr Pharma, Inc.